Sustained Weight Loss with Vagal Nerve Blockade but Not with Sham: 18-Month Results of the ReCharge Trial
Table 1
Baseline characteristics by treatment group.
vBloc
Sham control
Demographics
Women, number (%)
141 (87)
62 (81)
Age, mean (SD), y
47 (10)
47 (9)
Ethnicity, number (%)
Caucasian
149 (92)
73 (95)
African American
8 (5)
3 (4)
Native American
2 (1)
1 (1)
Asian
1 (1)
1 (1)
Hawaiian/Pacific Islander
1 (1)
0 (0)
General medical
Body size measures at implant, mean (SD)
Height, cm
166 (8)
168 (9)
Implant weight, kg
113 (13)
116 (14)
BMI, kg/m2
41 (3)
41 (3)
Excess weighta, kg
44 (9)
45 (10)
Waist circumference, cm
121 (12)
123 (11)
Type 2 diabetes mellitus, number (%)
7 (4)
5 (7)
Hypertension, number (%)
63 (39)
32 (42)
Dyslipidemia, number (%)
91 (56)
46 (60)
Obstructive sleep apnea, number (%)
33 (20)
23 (30)
Excess weight was calculated as the difference between the weight at the time of implantation and the ideal body weight corresponding to a BMI of 25 kg/m2.